Incyte CORP Form 4 insider transactions

Incyte Corp's EVP & Chief Medical Officer, Steven H. Stein, disposed of 13,292 shares of common stock to cover tax withholding obligations.

Incyte's EVP of Technology Operations, Michael James Morrissey, disposed of 254 shares of common stock to cover tax withholding obligations related to restricted stock unit settlement.

Incyte Corp. Director Paul J. Clancy acquired 241 shares of common stock at $98.77 per share through a pre-arranged stock incentive plan.

Incyte Corp. Director Edmund Harrigan acquired 245 shares of common stock at $98.77 per share as part of a pre-arranged equity compensation plan.

Julian C. Baker, a director and 10% owner of Incyte Corp, received 328 shares of common stock in lieu of quarterly director retainer fees, as reported in a recent SEC Form 4 filing.

Incyte's Principal Accounting Officer, Tray Thomas, reported planned exercises of stock options and sales of common stock under a 10b5-1 plan.

Incyte's EVP, Head of Tech. Operations, Michael James Morrissey, sold a total of 58,331 shares of common stock in pre-planned transactions on December 16 and 17, 2025.

Incyte's EVP & Chief Scientific Officer, Patrick A. Mayes, sold 5,808 shares of common stock in two transactions under a pre-arranged 10b5-1 trading plan.

Incyte Corp. Director Herve Hoppenot reported a tax-related disposition of 2,843 common shares at $96.7, maintaining a beneficial ownership of 326,803 shares.

Incyte's EVP & Chief Medical Officer, Steven H. Stein, sold a total of 22,664 shares of common stock and had 17,093 shares withheld for taxes in early December 2025, pursuant to a Rule 10b5-1 plan.

Incyte's EVP, Head of Tech. Operations, Michael James Morrissey, reported the disposition of 326 common shares to cover tax withholding obligations related to restricted stock units.

Incyte Corporation's EVP & General Counsel, Richard A. Hoffman, was granted restricted stock units, stock options, and performance shares effective December 1, 2025.

Incyte's Principal Accounting Officer, Tray Thomas, reported the sale of 769 shares of common stock across two transactions in late November 2025.

Incyte's EVP and General Counsel, Sheila A. Denton, exercised stock options and subsequently sold an equal number of common shares on November 17, 2025, under a Rule 10b5-1 plan.

Incyte Corp Director Herve Hoppenot reported the planned sale of 187,500 shares of common stock at $105.46 per share, executed under a pre-arranged 10b5-1 plan.

Incyte's EVP & Chief Medical Officer, Steven H. Stein, exercised stock options and subsequently sold 5,233 shares of common stock for liquidity and diversification.

Incyte's EVP and General Counsel, Sheila A. Denton, exercised stock options and subsequently sold an equal number of common shares under a pre-arranged 10b5-1 plan.

Incyte Corp's EVP, Head of Incyte International, Heeson Lee, sold 3,074 shares of common stock for $94.02 per share under a Rule 10b5-1 plan.

Incyte's EVP & General Counsel, Sheila A. Denton, exercised stock options and subsequently sold an equal number of common shares.

Incyte's EVP & General Counsel, Sheila A. Denton, reported exercising stock options and subsequently selling shares, including shares withheld for tax obligations, under a Rule 10b5-1 plan.

Incyte's EVP & Chief Scientific Officer, Patrick A. Mayes, disposed of 1,569 shares of common stock at $86.7 per share to cover tax withholding obligations related to restricted stock units.

Incyte Corp's EVP, Head of Incyte International, Lee Heeson, disposed of 463 common shares to cover tax withholding obligations at a price of $86.7 per share.

Baker Bros. Advisors and affiliated entities reported the acquisition of Incyte Corp common stock by Julian C. Baker in lieu of director fees, detailing complex beneficial ownership structures.

Incyte Director Paul J. Clancy acquired 285 shares of common stock at $84.81 per share on September 30, 2025, increasing his total beneficial ownership to 23,235 shares.

Incyte Corporation Director Edmund Harrigan acquired 289 shares of common stock valued at $84.81 per share, increasing his beneficial ownership.

Incyte's Chief Strategy Officer, David H. Gardner, received substantial equity awards including restricted stock units, performance shares, and stock options.

Incyte's EVP & General Counsel, Sheila A. Denton, executed a pre-planned transaction, exercising stock options and selling an equal number of shares.

Incyte's EVP & General Counsel, Sheila A. Denton, exercised stock options and immediately sold an equal number of shares under a pre-arranged 10b5-1 plan.

Incyte's EVP of Human Resources, Ramitpal K Basi, was granted restricted stock units, performance shares, and stock options on August 25, 2025.

Incyte's EVP & General Counsel, Sheila A. Denton, exercised stock options and sold a portion of common stock under a pre-arranged 10b5-1 trading plan.